Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 254


Hypoxia-inducible factor-2 alpha up-regulates CD70 under hypoxia and enhances anchorage-independent growth and aggressiveness in cancer cells.

Kitajima S, Lee KL, Fujioka M, Sun W, You J, Chia GS, Wanibuchi H, Tomita S, Araki M, Kato H, Poellinger L.

Oncotarget. 2018 Apr 10;9(27):19123-19135. doi: 10.18632/oncotarget.24919. eCollection 2018 Apr 10.


The role of CD27-CD70-mediated T cell co-stimulation in vasculogenesis, arteriogenesis and angiogenesis.

Simons KH, Aref Z, Peters HAB, Welten SP, Nossent AY, Jukema JW, Hamming JF, Arens R, de Vries MR, Quax PHA.

Int J Cardiol. 2018 Jun 1;260:184-190. doi: 10.1016/j.ijcard.2018.02.015.


CD70 as a target for chimeric antigen receptor T cells in head and neck squamous cell carcinoma.

Park YP, Jin L, Bennett KB, Wang D, Fredenburg KM, Tseng JE, Chang LJ, Huang J, Chan EKL.

Oral Oncol. 2018 Mar;78:145-150. doi: 10.1016/j.oraloncology.2018.01.024. Epub 2018 Feb 20.


CD70 Deficiency due to a Novel Mutation in a Patient with Severe Chronic EBV Infection Presenting As a Periodic Fever.

Caorsi R, Rusmini M, Volpi S, Chiesa S, Pastorino C, Sementa AR, Uva P, Grossi A, Lanino E, Faraci M, Minoia F, Signa S, Picco P, Martini A, Ceccherini I, Gattorno M.

Front Immunol. 2018 Jan 29;8:2015. doi: 10.3389/fimmu.2017.02015. eCollection 2017.


CD70 encoded by modified vaccinia virus Ankara enhances CD8 T-cell-dependent protective immunity in MHC class II-deficient mice.

Bathke B, Pätzold J, Kassub R, Giessel R, Lämmermann K, Hinterberger M, Brinkmann K, Chaplin P, Suter M, Hochrein H, Lauterbach H.

Immunology. 2017 Dec 27. doi: 10.1111/imm.12884. [Epub ahead of print]


Preclinical data on the combination of cisplatin and anti-CD70 therapy in non-small cell lung cancer as an excellent match in the era of combination therapy.

Jacobs J, Deschoolmeester V, Rolfo C, Zwaenepoel K, Van den Bossche J, Deben C, Silence K, de Haard H, Hermans C, Rottey S, Vangestel C, Lardon F, Smits E, Pauwels P.

Oncotarget. 2017 May 23;8(43):74058-74067. doi: 10.18632/oncotarget.18202. eCollection 2017 Sep 26.


T Cell-Derived CD70 Delivers an Immune Checkpoint Function in Inflammatory T Cell Responses.

O'Neill RE, Du W, Mohammadpour H, Alqassim E, Qiu J, Chen G, McCarthy PL, Lee KP, Cao X.

J Immunol. 2017 Nov 15;199(10):3700-3710. doi: 10.4049/jimmunol.1700380. Epub 2017 Oct 18.


Down-regulation of MBD4 contributes to hypomethylation and overexpression of CD70 in CD4<sup>+</sup> T cells in systemic lupus erythematosus.

Liao W, Li M, Wu H, Jia S, Zhang N, Dai Y, Zhao M, Lu Q.

Clin Epigenetics. 2017 Sep 22;9:104. doi: 10.1186/s13148-017-0405-8. eCollection 2017.


Targeted alpha therapy using a novel CD70 targeted thorium-227 conjugate in <i>in vitro</i> and <i>in vivo</i> models of renal cell carcinoma.

Hagemann UB, Mihaylova D, Uran SR, Borrebaek J, Grant D, Bjerke RM, Karlsson J, Cuthbertson AS.

Oncotarget. 2017 Apr 7;8(34):56311-56326. doi: 10.18632/oncotarget.16910. eCollection 2017 Aug 22.


Expression of CD70 (CD27L) Is Associated With Epithelioid and Sarcomatous Features in IDH-Wild-Type Glioblastoma.

Pratt D, Pittaluga S, Palisoc M, Fetsch P, Xi L, Raffeld M, Gilbert MR, Quezado M.

J Neuropathol Exp Neurol. 2017 Aug 1;76(8):697-708. doi: 10.1093/jnen/nlx051.


Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies.

Aftimos P, Rolfo C, Rottey S, Offner F, Bron D, Maerevoet M, Soria JC, Moshir M, Dreier T, Van Rompaey L, Michot JM, Silence K, Hultberg A, Gandini D, de Haard H, Ribrag V, Peeters M, Thibault A, Leupin N, Awada A.

Clin Cancer Res. 2017 Nov 1;23(21):6411-6420. doi: 10.1158/1078-0432.CCR-17-0613. Epub 2017 Aug 1.


CD70 turns on NK cells to attack lymphoma.

Fehniger TA.

Blood. 2017 Jul 20;130(3):238-239. doi: 10.1182/blood-2017-06-786244. No abstract available.


CD70, a novel target of CAR T-cell therapy for gliomas.

Jin L, Ge H, Long Y, Yang C, Chang YE, Mu L, Sayour EJ, De Leon G, Wang QJ, Yang JC, Kubilis PS, Bao H, Xia S, Lu D, Kong Y, Hu L, Shang Y, Jiang C, Nie J, Li S, Gu Y, Sun J, Mitchell DA, Lin Z, Huang J.

Neuro Oncol. 2018 Jan 10;20(1):55-65. doi: 10.1093/neuonc/nox116.


Tumor associated CD70 expression is involved in promoting tumor migration and macrophage infiltration in GBM.

Ge H, Mu L, Jin L, Yang C, Chang YE, Long Y, DeLeon G, Deleyrolle L, Mitchell DA, Kubilis PS, Lu D, Qi J, Gu Y, Lin Z, Huang J.

Int J Cancer. 2017 Oct 1;141(7):1434-1444. doi: 10.1002/ijc.30830. Epub 2017 Jul 5.


Host-Derived CD70 Suppresses Murine Graft-versus-Host Disease by Limiting Donor T Cell Expansion and Effector Function.

Leigh ND, O'Neill RE, Du W, Chen C, Qiu J, Ashwell JD, McCarthy PL, Chen GL, Cao X.

J Immunol. 2017 Jul 1;199(1):336-347. doi: 10.4049/jimmunol.1502181. Epub 2017 May 26.


Effect of Lang-Chuang-Ding Decoction () on DNA Methylation of CD70 Gene Promoter in Peripheral Blood Mononuclear Cells of Female Patients with Systemic Lupus Erythematosus.

Sun J, Shao TJ, Zhang DY, Huang XQ, Xie ZJ, Wen CP.

Chin J Integr Med. 2018 May;24(5):348-352. doi: 10.1007/s11655-017-2804-2. Epub 2017 May 11.


CD70 reverse signaling enhances NK cell function and immunosurveillance in CD27-expressing B-cell malignancies.

Al Sayed MF, Ruckstuhl CA, Hilmenyuk T, Claus C, Bourquin JP, Bornhauser BC, Radpour R, Riether C, Ochsenbein AF.

Blood. 2017 Jul 20;130(3):297-309. doi: 10.1182/blood-2016-12-756585. Epub 2017 May 11.


Prognostic markers in oropharyngeal squamous cell carcinoma: focus on CD70 and tumour infiltrating lymphocytes.

De Meulenaere A, Vermassen T, Aspeslagh S, Zwaenepoel K, Deron P, Duprez F, Rottey S, Ferdinande L.

Pathology. 2017 Jun;49(4):397-404. doi: 10.1016/j.pathol.2017.02.002. Epub 2017 Apr 17.


CD70 and PD-L1 in anaplastic thyroid cancer - promising targets for immunotherapy.

Zwaenepoel K, Jacobs J, De Meulenaere A, Silence K, Smits E, Siozopoulou V, Hauben E, Rolfo C, Rottey S, Pauwels P.

Histopathology. 2017 Sep;71(3):357-365. doi: 10.1111/his.13230. Epub 2017 Jun 16.


CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia.

Riether C, Schürch CM, Bührer ED, Hinterbrandner M, Huguenin AL, Hoepner S, Zlobec I, Pabst T, Radpour R, Ochsenbein AF.

J Exp Med. 2017 Feb;214(2):359-380. doi: 10.1084/jem.20152008. Epub 2016 Dec 28.

Supplemental Content

Support Center